News und Analysen
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
EQS-News: Siltronic achieves annual targets for 2023
EQS-News: Siltronic achieves annual targets for 2023
EQS-News: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-News: Evotec SE: Invitation to Conference Call
EQS-News: Evotec SE: Invitation to Conference Call
EQS-News: Study on the frequency situation on the German mobile communications market shows: Adequate spectrum for the operation of four networks remains available
EQS-News: Study on the frequency situation on the German mobile communications market shows: Adequate spectrum for the operation of four networks remains available
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
EQS-Adhoc: United Internet with positive outlook for 2024
EQS-Adhoc: United Internet with positive outlook for 2024
EQS-News: Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
EQS-News: Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
EQS-News: Management Board and Supervisory Board jointly recommend acceptance of the voluntary public acquisition offer
EQS-News: Management Board and Supervisory Board jointly recommend acceptance of the voluntary public acquisition offer
EQS-News: CANCOM SE: Supervisory Board of the CANCOM Group reorganized
EQS-News: CANCOM SE: Supervisory Board of the CANCOM Group reorganized
EQS-Adhoc: CANCOM SE: Klaus Weinmann new Chairman of the Supervisory Board; previous Chairman of the Supervisory Board Stefan Kober resigns chairmanship
EQS-Adhoc: CANCOM SE: Klaus Weinmann new Chairman of the Supervisory Board; previous Chairman of the Supervisory Board Stefan Kober resigns chairmanship
EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study